Home > Healthcare > Medical Devices > Therapeutic Devices > Renal Denervation Market

Renal Denervation Market Trends

Report ID: GMI12780
Published Date: Dec 2024
Report Format: PDF

Download Free Sample

Renal Denervation Market Trends

The market is witnessing several transformative trends. The advent of dual-mode technologies, combining ultrasound and radiofrequency modalities, is improving procedural accuracy and safety.

Artificial intelligence and machine learning are being integrated into renal denervation systems to optimize patient outcomes and personalize treatments. Emerging markets, particularly in Asia-Pacific, are showcasing significant growth potential due to increasing healthcare access and awareness.
Additionally, there is a shift toward outpatient procedures for renal denervation, reducing costs and improving patient convenience. Enhanced imaging techniques during procedures are also gaining traction, enabling real-time monitoring and precision. The growing focus on combination therapies, where renal denervation is paired with pharmacological interventions, is another trend shaping the market. Key players are prioritizing partnerships and collaborations to expand market presence and accelerate product innovations.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global renal denervation industry was valued at USD 1.1 billion in 2024 and is projected to grow at a 28% CAGR from 2025 to 2034, driven by the increasing prevalence of hypertension and advancements in minimally invasive medical technologies.

The U.S. renal denervation market was valued at USD 407.2 million in 2024 and is expected to grow at a 26.6% CAGR from 2025 to 2034, supported by rising hypertension-related healthcare costs and innovative clinical trials conducted by leading institutions.

Renal denervation is gaining traction in the U.S. due to increasing hypertension-related healthcare costs, active clinical trials by institutions like the Mayo Clinic, and supportive reimbursement policies for cardiovascular health programs.

Key players in the renal denervation industry include Abbott, ABLATIVE SOLUTIONS, Boston Scientific, Johnson & Johnson, Medtronic, Otsuka, Recor, Symple Surgical, TERUMO, and VENUS MEDTECH.